Ascension MCP Approval Should Not Include Postmarket Study Requirement
This article was originally published in The Gray Sheet
Executive Summary
Ascension Orthopedics' ten-year follow-up data on the Ascension MCP total metacarpophalangeal finger joint replacement obviates the need for a postmarket study, according to FDA's Orthopedics and Rehabilitation Devices Advisory Panel.
You may also be interested in...
Ascension MCP Joint Replacement Approval Includes Follow-Up Requirement
FDA approval of Ascension Orthopedics' metacarpophalangeal (MCP) joint replacement device opens the door for Avanta Orthopedics to file a PMA for a second alternative to silicone rubber spacers
Ascension MCP Joint Replacement Approval Includes Follow-Up Requirement
FDA approval of Ascension Orthopedics' metacarpophalangeal (MCP) joint replacement device opens the door for Avanta Orthopedics to file a PMA for a second alternative to silicone rubber spacers
PyroCarbon MCP Joint May Provide Stiff Competition For Silicone Alternative
FDA approval of Ascension Orthopedics' PyroCarbon MCP (metacarpophalangeal prosthesis) total finger joint replacement would preclude the need for silicone MCP joint replacements in early-stage arthritis patients, the company claims.